Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 282 entries
Sorted by: Best Match Show Resources per page
Computational Analysis of the Mode of Action of Disopyramide and Quinidine on hERG-Linked Short QT Syndrome in Human Ventricles.

Frontiers in physiology

Whittaker DG, Ni H, Benson AP, Hancox JC, Zhang H.
PMID: 29085299
Front Physiol. 2017 Oct 04;8:759. doi: 10.3389/fphys.2017.00759. eCollection 2017.

The short QT syndrome (SQTS) is a rare cardiac disorder associated with arrhythmias and sudden death. Gain-of-function mutations to potassium channels mediating the rapid delayed rectifier current,

Cite
Whittaker DG, Ni H, Benson AP, et al. Computational Analysis of the Mode of Action of Disopyramide and Quinidine on hERG-Linked Short QT Syndrome in Human Ventricles. Front Physiol. 2017;8:759doi: 10.3389/fphys.2017.00759.
Whittaker, D. G., Ni, H., Benson, A. P., Hancox, J. C., & Zhang, H. (2017). Computational Analysis of the Mode of Action of Disopyramide and Quinidine on hERG-Linked Short QT Syndrome in Human Ventricles. Frontiers in physiology, 8759. https://doi.org/10.3389/fphys.2017.00759
Whittaker, Dominic G, et al. "Computational Analysis of the Mode of Action of Disopyramide and Quinidine on hERG-Linked Short QT Syndrome in Human Ventricles." Frontiers in physiology vol. 8 (2017): 759. doi: https://doi.org/10.3389/fphys.2017.00759
Whittaker DG, Ni H, Benson AP, Hancox JC, Zhang H. Computational Analysis of the Mode of Action of Disopyramide and Quinidine on hERG-Linked Short QT Syndrome in Human Ventricles. Front Physiol. 2017 Oct 04;8:759. doi: 10.3389/fphys.2017.00759. eCollection 2017. PMID: 29085299; PMCID: PMC5649182.
Copy Download .nbib Format: NLM
Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects.

Clinical pharmacology in drug development

Matsushima N, Lee F, Sato T, Weiss D, Mendell J.
PMID: 27121940
Clin Pharmacol Drug Dev. 2013 Oct;2(4):358-66. doi: 10.1002/cpdd.53. Epub 2013 Sep 09.

BACKGROUND: Edoxaban is an oral, once-daily, direct factor Xa inhibitor under investigation for stroke prevention in patients with atrial fibrillation and for treatment and secondary prevention of venous thromboembolism. This study evaluated edoxaban absolute bioavailability and effects of the...

Cite
Matsushima N, Lee F, Sato T, et al. Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects. Clin Pharmacol Drug Dev. 2013;2(4):358-66doi: 10.1002/cpdd.53.
Matsushima, N., Lee, F., Sato, T., Weiss, D., & Mendell, J. (2013). Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects. Clinical pharmacology in drug development, 2(4), 358-66. https://doi.org/10.1002/cpdd.53
Matsushima, Nobuko, et al. "Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects." Clinical pharmacology in drug development vol. 2,4 (2013): 358-66. doi: https://doi.org/10.1002/cpdd.53
Matsushima N, Lee F, Sato T, Weiss D, Mendell J. Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects. Clin Pharmacol Drug Dev. 2013 Oct;2(4):358-66. doi: 10.1002/cpdd.53. Epub 2013 Sep 09. PMID: 27121940.
Copy Download .nbib Format: NLM
Oral quinine sulfate for the treatment of electrical storm and prevention of recurrent shocks in Brugada syndrome after failed cilostazol therapy.

HeartRhythm case reports

Shenthar J, Chakali SS, Acharya D, Parvez J, Banavalikar B.
PMID: 29062700
HeartRhythm Case Rep. 2017 Aug 24;3(10):470-474. doi: 10.1016/j.hrcr.2017.07.005. eCollection 2017 Oct.

No abstract available.

Cite
Shenthar J, Chakali SS, Acharya D, et al. Oral quinine sulfate for the treatment of electrical storm and prevention of recurrent shocks in Brugada syndrome after failed cilostazol therapy. HeartRhythm Case Rep. 2017;3(10):470-474doi: 10.1016/j.hrcr.2017.07.005.
Shenthar, J., Chakali, S. S., Acharya, D., Parvez, J., & Banavalikar, B. (2017). Oral quinine sulfate for the treatment of electrical storm and prevention of recurrent shocks in Brugada syndrome after failed cilostazol therapy. HeartRhythm case reports, 3(10), 470-474. https://doi.org/10.1016/j.hrcr.2017.07.005
Shenthar, Jayaprakash, et al. "Oral quinine sulfate for the treatment of electrical storm and prevention of recurrent shocks in Brugada syndrome after failed cilostazol therapy." HeartRhythm case reports vol. 3,10 (2017): 470-474. doi: https://doi.org/10.1016/j.hrcr.2017.07.005
Shenthar J, Chakali SS, Acharya D, Parvez J, Banavalikar B. Oral quinine sulfate for the treatment of electrical storm and prevention of recurrent shocks in Brugada syndrome after failed cilostazol therapy. HeartRhythm Case Rep. 2017 Aug 24;3(10):470-474. doi: 10.1016/j.hrcr.2017.07.005. eCollection 2017 Oct. PMID: 29062700; PMCID: PMC5643860.
Copy Download .nbib Format: NLM
J Wave Syndrome: Clinical Diagnosis, Risk Stratification and Treatment.

Journal of atrial fibrillation

Sethi KK, Sethi K, Chutani SK.
PMID: 27957139
J Atr Fibrillation. 2014 Dec 31;7(4):1173. doi: 10.4022/jafib.1173. eCollection 2014 Dec.

J wave syndrome has emerged from a benign electrocardiographic abnormality to a proarrythmic state and a significant cause of idiopathic ventricular fibrillation responsible for sudden cardiac death. Electrical genesis, genetics and ionic mechanisms of J wave syndromes are active...

Cite
Sethi KK, Sethi K, Chutani SK. J Wave Syndrome: Clinical Diagnosis, Risk Stratification and Treatment. J Atr Fibrillation. 2014;7(4):1173doi: 10.4022/jafib.1173.
Sethi, K. K., Sethi, K., & Chutani, S. K. (2014). J Wave Syndrome: Clinical Diagnosis, Risk Stratification and Treatment. Journal of atrial fibrillation, 7(4), 1173. https://doi.org/10.4022/jafib.1173
Sethi, Kamal K, et al. "J Wave Syndrome: Clinical Diagnosis, Risk Stratification and Treatment." Journal of atrial fibrillation vol. 7,4 (2014): 1173. doi: https://doi.org/10.4022/jafib.1173
Sethi KK, Sethi K, Chutani SK. J Wave Syndrome: Clinical Diagnosis, Risk Stratification and Treatment. J Atr Fibrillation. 2014 Dec 31;7(4):1173. doi: 10.4022/jafib.1173. eCollection 2014 Dec. PMID: 27957139; PMCID: PMC5135207.
Copy Download .nbib Format: NLM
Improvement of chiral stationary phases based on cinchona alkaloids bonded to crown ethers by chiral modification.

Journal of separation science

Zhao J, Wu H, Wang D, Wu H, Cheng L, Jin Y, Ke Y, Liang X.
PMID: 26377616
J Sep Sci. 2015 Nov;38(22):3884-3890. doi: 10.1002/jssc.201500834. Epub 2015 Oct 15.

To improve the chiral recognition capability of a cinchona alkaloid crown ether chiral stationary phase, the crown ether moiety was modified by the chiral group of (1S, 2S)-2-aminocyclohexyl phenylcarbamate. Both quinine and quinidine-based stationary phases were evaluated by chiral...

Cite
Zhao J, Wu H, Wang D, et al. Improvement of chiral stationary phases based on cinchona alkaloids bonded to crown ethers by chiral modification. J Sep Sci. 2015;38(22):3884-3890doi: 10.1002/jssc.201500834.
Zhao, J., Wu, H., Wang, D., Wu, H., Cheng, L., Jin, Y., Ke, Y., & Liang, X. (2015). Improvement of chiral stationary phases based on cinchona alkaloids bonded to crown ethers by chiral modification. Journal of separation science, 38(22), 3884-3890. https://doi.org/10.1002/jssc.201500834
Zhao, Jianchao, et al. "Improvement of chiral stationary phases based on cinchona alkaloids bonded to crown ethers by chiral modification." Journal of separation science vol. 38,22 (2015): 3884-3890. doi: https://doi.org/10.1002/jssc.201500834
Zhao J, Wu H, Wang D, Wu H, Cheng L, Jin Y, Ke Y, Liang X. Improvement of chiral stationary phases based on cinchona alkaloids bonded to crown ethers by chiral modification. J Sep Sci. 2015 Nov;38(22):3884-3890. doi: 10.1002/jssc.201500834. Epub 2015 Oct 15. PMID: 26377616.
Copy Download .nbib Format: NLM
Asymmetric chlorination of 4-substituted pyrazolones catalyzed by natural cinchona alkaloid.

Chemical communications (Cambridge, England)

Bao X, Wei S, Zou L, He Y, Xue F, Qu J, Wang B.
PMID: 27711284
Chem Commun (Camb). 2016 Sep 15;52(76):11426-11429. doi: 10.1039/c6cc06236a.

A natural quinidine-catalyzed asymmetric chlorination of 4-substituted pyrazolones is developed, affording products with a quaternary chiral chlorine-attached carbon centre in high yield with excellent enantioselectivity. The low catalyst loading (1 mol%), broad substrate scope, and facile and valuable transformation...

Cite
Bao X, Wei S, Zou L, et al. Asymmetric chlorination of 4-substituted pyrazolones catalyzed by natural cinchona alkaloid. Chem Commun (Camb). 2016;52(76):11426-11429doi: 10.1039/c6cc06236a.
Bao, X., Wei, S., Zou, L., He, Y., Xue, F., Qu, J., & Wang, B. (2016). Asymmetric chlorination of 4-substituted pyrazolones catalyzed by natural cinchona alkaloid. Chemical communications (Cambridge, England), 52(76), 11426-11429. https://doi.org/10.1039/c6cc06236a
Bao, Xiaoze, et al. "Asymmetric chlorination of 4-substituted pyrazolones catalyzed by natural cinchona alkaloid." Chemical communications (Cambridge, England) vol. 52,76 (2016): 11426-11429. doi: https://doi.org/10.1039/c6cc06236a
Bao X, Wei S, Zou L, He Y, Xue F, Qu J, Wang B. Asymmetric chlorination of 4-substituted pyrazolones catalyzed by natural cinchona alkaloid. Chem Commun (Camb). 2016 Sep 15;52(76):11426-11429. doi: 10.1039/c6cc06236a. PMID: 27711284.
Copy Download .nbib Format: NLM
Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease.

American journal of neurodegenerative disease

Lauterbach EC.
PMID: 27073741
Am J Neurodegener Dis. 2016 Mar 01;5(1):29-51. eCollection 2016.

Anxiety is common in the Mild Cognitive Impairment (MCI) stage of Alzheimer's disease (AD) and the pre-motor stages of Parkinson's disease (PD). A concomitant and possible cause of this anxiety is microglial activation, also considered a key promoter of...

Cite
Lauterbach EC. Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. Am J Neurodegener Dis. 2016;5(1):29-51
Lauterbach, E. C. (2016). Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. American journal of neurodegenerative disease, 5(1), 29-51.
Lauterbach, Edward C. "Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease." American journal of neurodegenerative disease vol. 5,1 (2016): 29-51.
Lauterbach EC. Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. Am J Neurodegener Dis. 2016 Mar 01;5(1):29-51. eCollection 2016. PMID: 27073741; PMCID: PMC4788730.
Copy Download .nbib Format: NLM
Mixed ternary ion associate formation between xanthene dye, cinchona-alkaloid and quaternary ammonium ion and its application to the determination of trace amounts of quaternary ammonium salts in pharmaceuticals.

Talanta

Sakai T, Hirose A.
PMID: 18968897
Talanta. 2003 Jan 02;59(1):167-75. doi: 10.1016/s0039-9140(02)00474-5.

Xanthene dyes such as eosin and tetraiodofluorescein form 1:2 ion associates with quaternary ammonium ions at pH 7-9; however, the development of color in the organic solvent is poor. When a quaternary ammonium salt is added in the extractable...

Cite
Sakai T, Hirose A. Mixed ternary ion associate formation between xanthene dye, cinchona-alkaloid and quaternary ammonium ion and its application to the determination of trace amounts of quaternary ammonium salts in pharmaceuticals. Talanta. 2003;59(1):167-75doi: 10.1016/s0039-9140(02)00474-5.
Sakai, T., & Hirose, A. (2003). Mixed ternary ion associate formation between xanthene dye, cinchona-alkaloid and quaternary ammonium ion and its application to the determination of trace amounts of quaternary ammonium salts in pharmaceuticals. Talanta, 59(1), 167-75. https://doi.org/10.1016/s0039-9140(02)00474-5
Sakai, Tadao, and Hirose, Akihiko. "Mixed ternary ion associate formation between xanthene dye, cinchona-alkaloid and quaternary ammonium ion and its application to the determination of trace amounts of quaternary ammonium salts in pharmaceuticals." Talanta vol. 59,1 (2003): 167-75. doi: https://doi.org/10.1016/s0039-9140(02)00474-5
Sakai T, Hirose A. Mixed ternary ion associate formation between xanthene dye, cinchona-alkaloid and quaternary ammonium ion and its application to the determination of trace amounts of quaternary ammonium salts in pharmaceuticals. Talanta. 2003 Jan 02;59(1):167-75. doi: 10.1016/s0039-9140(02)00474-5. PMID: 18968897.
Copy Download .nbib Format: NLM
The use of 2,3-dichloro-5,6-dicyano-p-benzoquinone for the spectrophotometric determination of some cardiovascular drugs.

Talanta

Issa AS, Mahrous MS, Salam MA, Soliman N.
PMID: 18964385
Talanta. 1987 Jul;34(7):670-2. doi: 10.1016/0039-9140(87)80087-5.

Some basic cardiovascular drugs containing secondary or tertiary amino groups are determined spectrophotometrically. The method is simple and sensitive; it is based on the interaction of the drugs, as n-electron donors, with 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ) as a pi-acceptor. The highly...

Cite
Issa AS, Mahrous MS, Salam MA, et al. The use of 2,3-dichloro-5,6-dicyano-p-benzoquinone for the spectrophotometric determination of some cardiovascular drugs. Talanta. 1987;34(7):670-2doi: 10.1016/0039-9140(87)80087-5.
Issa, A. S., Mahrous, M. S., Salam, M. A., & Soliman, N. (1987). The use of 2,3-dichloro-5,6-dicyano-p-benzoquinone for the spectrophotometric determination of some cardiovascular drugs. Talanta, 34(7), 670-2. https://doi.org/10.1016/0039-9140(87)80087-5
Issa, A S, et al. "The use of 2,3-dichloro-5,6-dicyano-p-benzoquinone for the spectrophotometric determination of some cardiovascular drugs." Talanta vol. 34,7 (1987): 670-2. doi: https://doi.org/10.1016/0039-9140(87)80087-5
Issa AS, Mahrous MS, Salam MA, Soliman N. The use of 2,3-dichloro-5,6-dicyano-p-benzoquinone for the spectrophotometric determination of some cardiovascular drugs. Talanta. 1987 Jul;34(7):670-2. doi: 10.1016/0039-9140(87)80087-5. PMID: 18964385.
Copy Download .nbib Format: NLM
Treatment of pathologic laughing and crying.

Current treatment options in neurology

Wortzel HS, Anderson CA, Arciniegas DB.
PMID: 17716601
Curr Treat Options Neurol. 2007 Sep;9(5):371-80.

Pathologic laughing and crying (PLC) denotes paroxysms of involuntary and uncontrollable crying and/or laughing resulting from neurologic illnesses. These paroxysms of affect are often provoked by nonsentimental stimuli; even when the inciting stimulus is sentimentally meaningful, the intensity of...

Cite
Wortzel HS, Anderson CA, Arciniegas DB. Treatment of pathologic laughing and crying. Curr Treat Options Neurol. 2007;9(5):371-80
Wortzel, H. S., Anderson, C. A., & Arciniegas, D. B. (2007). Treatment of pathologic laughing and crying. Current treatment options in neurology, 9(5), 371-80.
Wortzel, Hal S, et al. "Treatment of pathologic laughing and crying." Current treatment options in neurology vol. 9,5 (2007): 371-80.
Wortzel HS, Anderson CA, Arciniegas DB. Treatment of pathologic laughing and crying. Curr Treat Options Neurol. 2007 Sep;9(5):371-80. PMID: 17716601.
Copy Download .nbib Format: NLM
MECHANISM OF SYNCOPE AND ACTION OF DRUGS IN COMPLETE HEART BLOCK.

California medicine

Nathanson MH, Miller H.
PMID: 18731818
Calif Med. 1952 Jun;76(6):370-5.

The syncopal attacks of complete heart block may be due either to ventricular standstill or to ventricular acceleration including fibrillation. As treatment may be harmful unless the underlying mechanism in each case is determined, it is important to apply...

Cite
Nathanson MH, Miller H. MECHANISM OF SYNCOPE AND ACTION OF DRUGS IN COMPLETE HEART BLOCK. Calif Med. 1952;76(6):370-5
Nathanson, M. H., & Miller, H. (1952). MECHANISM OF SYNCOPE AND ACTION OF DRUGS IN COMPLETE HEART BLOCK. California medicine, 76(6), 370-5.
Nathanson, M H, and Miller, H. "MECHANISM OF SYNCOPE AND ACTION OF DRUGS IN COMPLETE HEART BLOCK." California medicine vol. 76,6 (1952): 370-5.
Nathanson MH, Miller H. MECHANISM OF SYNCOPE AND ACTION OF DRUGS IN COMPLETE HEART BLOCK. Calif Med. 1952 Jun;76(6):370-5. PMID: 18731818; PMCID: PMC1521307.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayes M, Rabasseda X, Prous JR.
PMID: 16845450
Methods Find Exp Clin Pharmacol. 2006 Jun;28(5):323-43.

Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug...

Cite
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006;28(5):323-43
Bayes, M., Rabasseda, X., & Prous, J. R. (2006). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 28(5), 323-43.
Bayes, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 28,5 (2006): 323-43.
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Jun;28(5):323-43. PMID: 16845450.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 282 entries